1 citations
,
August 2023 in “Andrology” In this animal study, finasteride treatment altered testosterone metabolism in rat corpus cavernosum, linked to mechanisms of erectile dysfunction, but these changes were reversed after stopping the drug, suggesting post-treatment sexual side effects may relate more to central control dysfunction than peripheral issues.
October 2022 in “Biomolecules” This study found that in male rats, chronic finasteride treatment reduced allopregnanolone levels, which, upon drug withdrawal, correlated with increased pro-inflammatory cytokines and altered neurotransmitter levels.
2 citations
,
July 2021 in “The Journal of Sexual Medicine” This study found significant differences in gene expression, particularly in androgen receptor activity, between men with post-finasteride syndrome and healthy controls, suggesting a potential biological basis for the syndrome.
3 citations
,
April 2021 in “Journal of Medicinal Chemistry” This study suggests that finasteride may inhibit the enzyme PNMT, potentially contributing to its sexual and psychological side effects.
17 citations
,
September 2020 in “Journal of Endocrinological Investigation” This study found that the gut microbiota composition in patients with post-finasteride syndrome differs significantly from healthy controls, with reduced diversity and specific microbial changes, suggesting a potential diagnostic marker and therapeutic target.
7 citations
,
June 2020 in “Translational Andrology and Urology” This study evaluated potential penile vascular changes and persistent adverse effects in men discontinuing 5α-reductase inhibitors for androgenic alopecia, but no new clinical results were reported.
26 citations
,
December 2019 in “Neurobiology of Stress” This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.
37 citations
,
September 2018 in “Psychoneuroendocrinology” This study found that finasteride treatment in male rats led to enduring effects on depressive-like behavior, hippocampal neurogenesis and neuroinflammation, and gut microbiota composition after withdrawal.
58 citations
,
April 2017 in “The Journal of Steroid Biochemistry and Molecular Biology” This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.
14 citations
,
December 2016 in “Sexual Medicine” This study identified differences in adverse symptoms among patients with post-finasteride syndrome based on short and long androgen receptor gene polymorphisms.
50 citations
,
September 2016 in “The Journal of Clinical Endocrinology and Metabolism” This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.
21 citations
,
April 2016 in “Journal of Dermatological Treatment” This paper discusses the potential relationship between finasteride's adverse effects and factors like hand preference and sexual orientation, suggesting these could influence risk in male androgenic alopecia treatment, but reports no new clinical results.
33 citations
,
December 2015 in “Neuroendocrinology” This study found that subchronic finasteride treatment in male rats altered neuroactive steroid levels and steroid receptor expression in the brain, with some changes persisting after drug withdrawal.
111 citations
,
August 2015 in “Reviews in Endocrine and Metabolic Disorders” 5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.
44 citations
,
April 2015 in “PubMed” This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.
16 citations
,
September 2014 in “International Journal of Biological Markers” This study found that the less common CAG-rs4045402 and GGN-rs3138869 polymorphisms were more frequent in patients with post-finasteride syndrome and androgenetic alopecia, suggesting a genetic predisposition to AGA development.
36 citations
,
June 2014 in “PLOS ONE” This study found that men with persistent sexual side effects after using finasteride for androgenetic alopecia had higher androgen receptor expression in certain tissues compared to those who never used the drug.
81 citations
,
June 2014 in “American Journal of Men's Health” This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.
61 citations
,
April 2014 in “The Journal of Steroid Biochemistry and Molecular Biology” This study reports that men with androgenic alopecia experience altered neuroactive steroid levels associated with persistent depression symptoms even after stopping finasteride treatment.
73 citations
,
July 2013 in “The Journal of Sexual Medicine” This study observed that androgenic alopecia patients taking finasteride had altered neuroactive steroid levels and persistent depression symptoms even after stopping the treatment.
19 citations
,
November 2012 in “BJUI” In this study, researchers observed that the sexual effects of dihydrotestosterone deprivation using finasteride may vary by handedness, with right-handed men often experiencing lower sexual function and left-handed men showing no effect or improvement.
112 citations
,
July 2012 in “The Journal of Sexual Medicine” In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.
185 citations
,
March 2011 in “The Journal of Sexual Medicine” This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.
581 citations
,
October 1998 in “Journal of The American Academy of Dermatology” In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.
